Bloomberg News (1/6, Fisk, Feeley, Voreacos) reports, “Johnson & Johnson will pay more than $1 billion to the US and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal, according to people familiar with the matter.” Bloomberg continues, “J&J, the world’s largest health products company, reached an agreement last week with the US attorney in Philadelphia, according to the people, who weren’t authorized to speak about the matter. Negotiations over a possible criminal plea are still under way, they said. The US government has been investigating Risperdal sales practices since 2004, including allegations the company marketed the drug for unapproved uses, J&J has said in Securities and Exchange Commission filings.”
The Asbury Park (NJ) Press (1/6, Diamond) reports, “Johnson & Johnson has had mixed results at trial,” having lost cases in South Carolina and Louisiana but winning in Pennsylvania and West Virginia. Reuters (1/6, Krauskopf) also covers this story.
From AAJ News